How Pharma CEOs Delegate Business Development and Licensing
Business development and licensing is where pharma CEOs most frequently find their delegation instincts colliding with organizational necessity. The deals are large, the strategic implications are significant, and the CEO’s scientific and commercial judgment is often genuinely additive. At the same time, a CEO who is personally involved in every BD interaction, every term sheet review, and every licensing conversation is not building a BD function. They are being one.
The question is not whether to delegate pharma BD and licensing. The question is how to design an authority structure that puts a capable Chief Business Officer or BD team in the lead on deal sourcing, early-stage evaluation, and routine partnership management, while preserving the CEO’s role in the high-stakes decisions where their personal involvement creates real value.
The CBO’s Role: Leading the BD Function, Not Supporting the CEO
Many pharma CEOs hire a Chief Business Officer and then continue to lead BD themselves, with the CBO functioning as a senior support resource. This is a delegation failure. It wastes a senior leadership investment and signals to the organization that the CEO does not trust the BD function.
A properly delegated CBO leads the BD function. They own the deal sourcing strategy, the pipeline of opportunities, the relationship network with potential partners, the term sheet negotiation process, and the day-to-day management of existing licensing relationships. The CEO is a resource the CBO deploys strategically, not the other way around.
This requires the CEO to be deliberate about which decisions they retain and which they hand off. The instinct to stay closely involved in every promising deal is understandable, but it comes at a cost: the CBO cannot develop the judgment and relationships needed to lead a world-class BD function if the CEO is always in the room.
Deal Size Authority: Setting the Right Thresholds
The most direct mechanism for structuring BD delegation is deal size authority. Every BD and licensing decision should have a clear answer to who can approve it.
Tier 1: CBO Authority Without CEO Involvement
The CBO should have authority to execute a defined class of BD transactions without CEO approval. This typically includes:
Collaboration agreements below a defined upfront payment threshold, often $5 million to $10 million for a mid-sized pharmaceutical company, where the strategic fit is within the approved partnership strategy.
License-in agreements for early-stage assets below a defined financial commitment and where the asset profile is consistent with the portfolio strategy the CEO has approved.
Non-disclosure agreements and due diligence arrangements. The CBO should be able to execute NDAs and initiate due diligence without CEO sign-off. Requiring CEO approval at this stage creates unnecessary friction in deal sourcing.
Research collaboration agreements with academic institutions and biotech partners below a defined annual value, typically $1 million to $3 million.
Renewals and amendments of existing licensing agreements where the financial terms are not materially changing and the relationship is in good standing.
Tier 2: CEO Approval Required Before Execution
Above the CBO’s independent authority threshold, the CEO becomes a required approver. This tier typically includes:
Licensing agreements with upfront payments, milestone commitments, or royalty structures that exceed the Tier 1 threshold.
New platform technology access agreements that could affect the company’s development strategy across multiple programs.
Co-promotion and co-commercialization agreements that involve significant commercial investment or revenue sharing.
Any agreement that creates exclusivity commitments in a therapeutic area or geography where the company has active or planned programs.
The CEO should not be rubber-stamping these decisions. By the time an agreement reaches CEO approval, the CBO should have completed full diligence, negotiated the key terms, and be presenting the CEO with a clear recommendation and the basis for it. CEO review at this stage should focus on strategic fit and risk, not on understanding the deal for the first time.
Tier 3: CEO and Board Required
A third category of transactions requires both CEO approval and board notification or approval:
Major licensing transactions above a defined size, often $50 million or more in total potential deal value, where the commitment is financially material to the company.
In-licensing or acquisition of late-stage or commercial-stage assets where the development risk has been substantially de-risked and the financial commitment is significant.
Out-licensing of major assets, particularly commercial-stage products, where the decision to partner rather than retain internal rights involves significant strategic and financial trade-offs.
Partnership structures that involve equity exchange, joint venture creation, or governance-level commitments to a partner company.
Pharma CEO commercial operations delegation covers how commercial partnership decisions interact with the BD and licensing governance structure described here.
Term Sheet Authority: The Critical Negotiation Stage
The term sheet is where the most consequential negotiation work happens in pharma BD. Getting the term sheet right determines the structure of the deal. Getting the authority structure around term sheets wrong creates delays, confusion with counterparties, and lost deals.
CBO Authority at Term Sheet Stage
The CBO should have authority to issue and negotiate non-binding term sheets for deals within their approval authority. This is essential for deal momentum. A counterparty who receives a term sheet and then watches it sit unanswered while CEO review is scheduled is a counterparty who may move on.
For larger deals that will require CEO approval before execution, the CBO should be able to develop and discuss a term sheet with the counterparty while the CEO is updated in parallel. The CEO should be engaged in the term sheet conversation before material commitments are made, but the CBO should not need CEO approval to open term sheet discussions.
CEO Involvement at Term Sheet Stage for Major Deals
For transactions above a defined materiality threshold, the CEO should be involved in term sheet strategy before the term sheet is issued. This does not mean the CEO writes the term sheet. It means the CEO and CBO align on the key terms the company will accept, the terms it will not, and the negotiation posture before the counterparty sees a document.
Some pharma CEOs choose to be personally present in key term sheet negotiation sessions for major deals. This can be appropriate where the CEO’s credibility and relationship adds tangible value to the negotiation. The CEO should make this choice deliberately, not as a reflex.
Board Communication About Term Sheets
The board’s role at term sheet stage is typically limited to awareness rather than approval, except for transactions that are individually material to the company. The CEO should keep the board chairman or lead director informed about major transactions in process, even before term sheets are executed. Surprises at board level in major BD transactions are avoidable with a simple practice of regular informal updates.
Partnership and M&A Decisions Requiring CEO and Board Involvement
The largest and most consequential BD decisions in pharma are those that are transformative rather than incremental. These decisions should never be delegated to the CBO, not because the CBO lacks judgment, but because the decisions involve trade-offs that only the CEO and board can make with the full organizational context.
Strategic Platform Partnerships
When a partnership is not just about a specific asset but about accessing a technology platform, a therapeutic area capability, or a commercial channel that will shape the company’s strategy for years, the CEO must be personally leading the decision. The CBO sources, develops, and negotiates. The CEO decides.
Platform partnerships frequently involve governance commitments, equity stakes, and strategic dependencies that go beyond conventional deal structures. The board should be involved in understanding these partnerships before they are executed, even if formal board approval is not required by the by-laws.
Mergers and Acquisitions
M&A is categorically different from licensing and partnership transactions. An acquisition is not a BD function output. It is a strategic decision that involves the company’s capital structure, governance, and long-term organizational identity.
The CBO may have a sourcing and analytical role in M&A, particularly in identifying acquisition targets and conducting preliminary diligence. But the M&A decision process is a CEO-led process with board oversight, not a BD function transaction.
The CEO should ensure that the CBO understands the boundary between BD and M&A clearly, both in terms of their role and in terms of the organizational processes that govern each.
Asset Divestitures and Out-Licensing of Core Assets
When the company considers out-licensing a program that was previously intended for internal development, or divesting an asset that represents significant pipeline value, the CEO and board must be central to the decision. These are portfolio strategy decisions, not transaction execution decisions. The CBO manages the transaction process once the strategic decision is made, but should not be making the strategic portfolio call.
Clinical development team delegation frameworks show how portfolio investment decisions at the program level interact with BD and licensing strategy.
Managing Existing Licensing Relationships
BD is often talked about in the context of new transactions, but managing existing licensing relationships is a significant ongoing responsibility. The delegation structure for relationship management needs explicit attention.
CBO Authority for Relationship Management
The CBO should own the management of existing licensing relationships as a standard function, including regular partner meetings, monitoring of milestone events and payment obligations, and handling routine amendments or questions within existing agreement parameters.
For major partnerships, the CEO’s visible involvement in annual or semi-annual strategic reviews with the partner’s most senior leadership is valuable. This is not operational management. It is relationship maintenance at a level that signals organizational commitment to the partnership.
Escalation Triggers for Relationship Issues
The CBO should have clear escalation criteria for when CEO involvement in a partner relationship is required: a dispute about contract interpretation that could affect material milestones, a partner’s change of control that affects the licensing relationship, a partner’s request for renegotiation of key commercial terms, or a partner’s underperformance on commercial obligations.
At these escalation points, the CEO needs to be in the conversation, but the CBO should have developed the company’s position and options before the escalation.
Building a BD Culture That Scales
A delegation matrix for BD and licensing is ultimately about building a function that can source, evaluate, and execute partnership transactions at the pace and quality the company’s strategy requires. No CEO can do this alone. The function has to work without the CEO in every deal.
A useful benchmark comes from research on high-performing pharmaceutical business development functions, including analysis in publications like Harvard Business Review on deal capability building, which consistently shows that the quality of the CBO and the BD team’s independent judgment is the most reliable predictor of deal quality over time. Delegating real authority to the CBO is not just an efficiency decision. It is an investment in deal quality.
This requires the CEO to be honest about whether they are delegating or supervising. Reviewing every term sheet, attending every counterparty meeting, and weighing in on every deal evaluation is supervision, not delegation. Real delegation means the CBO sources the deal, evaluates it, negotiates the term sheet, and presents the CEO with a recommendation, and the CEO’s job is to decide, not to re-run the analysis.
Governance Infrastructure for BD Delegation
For BD delegation to function well, three governance elements need to be in place:
A documented deal approval authority matrix that every member of the BD team understands. The matrix should specify financial thresholds, strategic criteria that affect authority level, and escalation requirements.
A regular BD pipeline review with the CEO where the CBO presents the current opportunity pipeline, deal status, and strategic priorities. This keeps the CEO informed without requiring CEO involvement in every deal.
A board communication practice that keeps the board appropriately updated on major transactions in process, completed deals, and significant partnership developments without requiring board approval for operational-level transactions.
Conclusion
Effective BD and licensing delegation for pharma CEOs means giving the CBO and BD team the authority to move at deal pace on transactions within defined parameters, while maintaining CEO and board involvement in decisions that are transformative, financially material, or strategically consequential.
The CEO who delegates effectively in BD does not step back from BD strategy. They step up from deal administration. Their role is to set the partnership strategy, maintain the most important counterparty relationships, and make the high-stakes decisions that can only be made with full organizational authority. Everything else belongs to the CBO.
Related Reading
For further context, explore How Pharma CEOs Delegate Clinical Trial Operations and How Pharma CEOs Delegate Commercial Launch and Sales Operations.